Site of effect of LY2951742 for migraine prophylaxis

The Lancet Neurology

Volumn 14, Issue 1, 2015, Pages 31-32

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; MONOCLONAL ANTIBODY;

ANTAGONISTS AND INHIBITORS; FEMALE; HUMAN; MALE; MIGRAINE DISORDERS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS;

EID: 84918564033     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70306-0     Document Type: Letter

References (5)

1. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
2. Yu YJ, Watts RJ Developing therapeutic antibodies for neurodegenerative disease. Neurotheraeutics 2013, 10:459-472.
3. Reuter U Anti-CGRP antibodies: a new approach to migraine treatment. Lancet Neurol 2014, 13:857-859.
4. Edvinsson L, Tfelt-Hansen P The blood-brain barrier in migraine treatment. Cephalalgia 2008, 28:1245-1258.
5. Sanchez del Rio M, Bakker D, et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999, 19:701-707.